Insulin treatment attenuates renal ADAM17 and ACE2 shedding in diabetic Akita mice

American Journal of Physiology - Renal Physiology

Volumn 306, Issue 6, 2014, Pages

  Salem, Esam S B ^a   Grobe, Nadja ^a   Elased, Khalid M ^a  

^a WRIGHT STATE UNIVERSITY   (United States)

Author keywords

ADAM17; Albuminuria; Diabetic akita mice; Renal and urinary ACE2; TIMP3

Indexed keywords

ANGIOTENSIN CONVERTING ENZYME 2; CREATININE; GLUCAGON; GLUCOSE; INSULIN; TISSUE INHIBITOR OF METALLOPROTEINASE 3; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA CONVERTING ENZYME; ADAM PROTEIN; DIPEPTIDE; DIPEPTIDYL CARBOXYPEPTIDASE; HYDROXAMIC ACID; N ((2 (HYDROXYAMINOCARBONYL)METHYL) 4 METHYLPENTANOYL) 3 (2' NAPHTHYL)ALANYLALANINE, 2 AMINOETHYLAMIDE; N-((2-(HYDROXYAMINOCARBONYL)METHYL)-4-METHYLPENTANOYL)-3-(2'-NAPHTHYL)ALANYLALANINE, 2-AMINOETHYLAMIDE; TUMOR NECROSIS FACTOR-ALPHA CONVERTASE;

ALBUMINURIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CARDIOVASCULAR RISK; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIABETIC NEPHROPATHY; DISEASE MARKER; GLUCOSE BLOOD LEVEL; HYPERGLYCEMIA; IMMUNOHISTOCHEMISTRY; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN IMPLANT; INSULIN TREATMENT; KIDNEY HYPERTROPHY; KIDNEY PROXIMAL TUBULE; KIDNEY TUBULE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; WESTERN BLOTTING; ADAM17; ANIMAL; CELL LINE; DIABETES MELLITUS; DIABETIC AKITA MICE; DRUG ANTAGONISM; HUMAN; METABOLISM; PATHOPHYSIOLOGY; RENAL AND URINARY ACE2; TIMP3; URINE;

ADAM17; ALBUMINURIA; DIABETIC AKITA MICE; RENAL AND URINARY ACE2; TIMP3;

ADAM PROTEINS; ANIMALS; CELL LINE; DIABETES MELLITUS; DIABETIC NEPHROPATHIES; DIPEPTIDES; HUMANS; HYDROXAMIC ACIDS; INSULIN; MALE; MICE; PEPTIDYL-DIPEPTIDASE A;

EID: 84899818343     PISSN: 1931857X     EISSN: 15221466     Source Type: Journal    
DOI: 10.1152/ajprenal.00516.2013     Document Type: Article

References (62)

1. Anonymous. The effect of intensive treatment of diabetes on the development, and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med 329: 977-986, 1993.
2. Arita DY, Cunha TS, Perez JD, Colucci JA, Ronchi FA, Nogueira MD, Arita LS, Aragao DS, Teixeira VP, Casarini DE. Overexpression of urinary N-domain ACE in chronic kidney dysfunction in Wistar rats. Clin Exp Hypertens 34: 389-396, 2012.
3. Basu R, Lee J, Wang Z, Patel VB, Fan D, Das SK, Liu GC, John R, Scholey JW, Oudit GY, Kassiri Z. Loss of TIMP3 selectively exacerbates diabetic nephropathy. Am J Physiol Renal Physiol 303: F1341-F1352, 2012.
4. Brezar V, Culina S, Gagnerault MC, Mallone R. Short-term subcutaneous insulin treatment delays but does not prevent diabetes in NOD mice. Eur J Immunol 42: 1553-1561, 2012.
5. Cardellini M, Menghini R, Luzi A, Davato F, Cardolini I, D'Alfonso R, Gentileschi P, Rizza S, Marini MA, Porzio O, Lauro D, Sbraccia P, Lauro R, Federici M. Decreased IRS2 and TIMP3 expression in monocytes from offspring of type 2 diabetic patients is correlated with insulin resistance and increased intima-media thickness. Diabetes 60: 3265-3270, 2011.
6. Cardellini M, Menghini R, Martelli E, Casagrande V, Marino A, Rizza S, Porzio O, Mauriello A, Solini A, Ippoliti A, Lauro R, Folli F, Federici M. TIMP3 is reduced in atherosclerotic plaques from subjects with type 2 diabetes and increased by SirT1. Diabetes 58: 2396-2401, 2009.
7. Chang JH, Paik SY, Mao L, Eisner W, Flannery PJ, Wang L, Tang Y, Mattocks N, Hadjadj S, Goujon JM, Ruiz P, Gurley SB, Spurney RF. Diabetic kidney disease in FVB/NJ Akita mice: temporal pattern of kidney injury and urinary nephrin excretion. PLoS One 7: e33942, 2012.
8. Chang SY, Chen YW, Chenier I, Tran SM, Zhang SL. Angiotensin II type II receptor deficiency accelerates the development of nephropathy in type I diabetes via oxidative stress and ACE2. Exp Diabetes Res 2011: 521076, 2011.
9. Chawla T, Sharma D, Singh A. Role of the renin angiotensin system in diabetic nephropathy. World J Diabetes 1: 141-145, 2010.
10. Chodavarapu H, Grobe N, Somineni HK, Salem ES, Madhu M, Elased KM. Rosiglitazone treatment of type 2 diabetic db/db mice attenuates urinary albumin and angiotensin converting enzyme 2 excretion. PLoS One 8: e62833, 2013.
11. de Galan BE, Perkovic V, Ninomiya T, Pillai A, Patel A, Cass A, Neal B, Poulter N, Harrap S, Mogensen CE, Cooper M, Marre M, Williams B, Hamet P, Mancia G, Woodward M, Glasziou P, Grobbee DE, MacMahon S, Chalmers J. Lowering blood pressure reduces renal events in type 2 diabetes. J Am Soc Nephrol 20: 883-892, 2009.
12. Dilauro M, Zimpelmann J, Robertson SJ, Genest D, Burns KD. Effect of ACE2 and angiotensin-(1-7) in a mouse model of early chronic kidney disease. Am J Physiol Renal Physiol 298: F1523-F1532, 2010.
13. Donoghue M, Hsieh F, Baronas E, Godbout K, Gosselin M, Stagliano N, Donovan M, Woolf B, Robison K, Jeyaseelan R, Breitbart RE, Acton S. A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1-9. Circ Res 87: E1-E9, 2000.
14. Ewens KG, George RA, Sharma K, Ziyadeh FN, Spielman RS. Assessment of 115 candidate genes for diabetic nephropathy by transmission/ disequilibrium test. Diabetes 54: 3305-3318, 2005.
15. Federici M, Hribal ML, Menghini R, Kanno H, Marchetti V, Porzio O, Sunnarborg SW, Rizza S, Serino M, Cunsolo V, Lauro D, Mauriello A, Smookler DS, Sbraccia P, Sesti G, Lee DC, Khokha R, Accili D, Lauro R. Timp3 deficiency in insulin receptor-haploinsufficient mice promotes diabetes and vascular inflammation via increased TNF-alpha. J Clin Invest 115: 3494-3505, 2005.
16. Fiorentino L, Cavalera M, Menini S, Marchetti V, Mavilio M, Fabrizi M, Conserva F, Casagrande V, Menghini R, Pontrelli P, Arisi I, D'Onofrio M, Lauro D, Khokha R, Accili D, Pugliese G, Gesualdo L, Lauro R, Federici M. Loss of TIMP3 underlies diabetic nephropathy via FoxO1/STAT1 interplay. EMBO Mol Med 5: 441-455, 2013.
17. Fiorentino L, Vivanti A, Cavalera M, Marzano V, Ronci M, Fabrizi M, Menini S, Pugliese G, Menghini R, Khokha R, Lauro R, Urbani A, Federici M. Increased tumor necrosis factor alpha-converting enzyme activity induces insulin resistance and hepatosteatosis in mice. Hepatology 51: 103-110, 2010.
18. Ford BM, Eid AA, Gooz M, Barnes JL, Gorin YC, Abboud HE. ADAM17 mediates Nox4 expression and NADPH oxidase activity in the kidney cortex of OVE26 mice. Am J Physiol Renal Physiol 305: F323-F332, 2013.
19. Grobe N, Elased KM, Cool DR, Morris M. Mass spectrometry for the molecular imaging of angiotensin metabolism in kidney. Am J Physiol Endocrinol Metab 302: E1016-E1024, 2012.
20. Gurley SB, Coffman TM. The renin-angiotensin system and diabetic nephropathy. Semin Nephrol 27: 144-152, 2007.
21. Hoffmann S, Podlich D, Hahnel B, Kriz W, Gretz N. Angiotensin II type 1 receptor overexpression in podocytes induces glomerulosclerosis in transgenic rats. J Am Soc Nephrol 15: 1475-1487, 2004.
22. Jia HP, Look DC, Tan P, Shi L, Hickey M, Gakhar L, Chappell MC, Wohlford-Lenane C, McCray PB Jr. Ectodomain shedding of angiotensin converting enzyme 2 in human airway epithelia. Am J Physiol Lung Cell Mol Physiol 297: L84-L96, 2009.
23. Jim B, Santos J, Spath F, Cijiang HJ. Biomarkers of diabetic nephropathy, the present and the future. Curr Diabetes Rev 8: 317-328, 2012.
24. Kobori H, Urushihara M. Augmented intrarenal and urinary angiotensinogen in hypertension and chronic kidney disease. Pflügers Arch 465: 3-12, 2013.
25. Koitka A, Cooper ME, Thomas MC, Tikellis C. Angiotensin converting enzyme 2 in the kidney. Clin Exp Pharmacol Physiol 35: 420-425, 2008.
26. Lai ZW, Hanchapola I, Steer DL, Smith AI. Angiotensin-converting enzyme 2 ectodomain shedding cleavage-site identification: determinants and constraints. Biochemistry 50: 5182-5194, 2011.
27. Lambert DW, Yarski M, Warner FJ, Thornhill P, Parkin ET, Smith AI, Hooper NM, Turner AJ. Tumor necrosis factor-alpha convertase (ADAM17) mediates regulated ectodomain shedding of the severe-acute respiratory syndrome-coronavirus (SARS-CoV) receptor, angiotensinconverting enzyme-2 (ACE2). J Biol Chem 280: 30113-30119, 2005.
28. Lautrette A, Li S, Alili R, Sunnarborg SW, Burtin M, Lee DC, Friedlander G, Terzi F. Angiotensin II and EGF receptor cross-talk in chronic kidney diseases: a new therapeutic approach. Nat Med 11: 867-874, 2005.
29. Leehey DJ, Singh AK, Bast JP, Sethupathi P, Singh R. Glomerular renin angiotensin system in streptozotocin diabetic and Zucker diabetic fatty rats. Transl Res 151: 208-216, 2008.
30. Lew RA, Warner FJ, Hanchapola I, Yarski MA, Manohar J, Burrell LM, Smith AI. Angiotensin-converting enzyme 2 catalytic activity in human plasma is masked by an endogenous inhibitor. Exp Physiol 93: 685-693, 2008.
31. Liu CX, Hu Q, Wang Y, Zhang W, Ma ZY, Feng JB, Wang R, Wang XP, Dong B, Gao F, Zhang MX, Zhang Y. Angiotensin-converting enzyme (ACE) 2 overexpression ameliorates glomerular injury in a rat model of diabetic nephropathy: a comparison with ACE inhibition. Mol Med 17: 59-69, 2011.
32. Lo CS, Liu F, Shi Y, Maachi H, Chenier I, Godin N, Filep JG, Ingelfinger JR, Zhang SL, Chan JS. Dual RAS blockade normalizes angiotensin-converting enzyme-2 expression and prevents hypertension and tubular apoptosis in Akita angiotensinogen-transgenic mice. Am J Physiol Renal Physiol 302: F840-F852, 2012.
33. Lv J, Perkovic V, Foote CV, Craig ME, Craig JC, Strippoli GF. Antihypertensive agents for preventing diabetic kidney disease. Cochrane Database Syst Rev 12: CD004136, 2012.
34. Melenhorst WB, Visser L, Timmer A, van den Heuvel MC, Stegeman CA, van GH. ADAM17 upregulation in human renal disease: a role in modulating TGF-_ availability? Am J Physiol Renal Physiol 297: F781-F790, 2009.
35. Mizuiri S, Aoki T, Hemmi H, Arita M, Sakai K, Aikawa A. Urinary angiotensin-converting enzyme 2 in patients with CKD. Nephrology (Carlton) 16: 567-572, 2011.
36. Mizuiri S, Hemmi H, Arita M, Ohashi Y, Tanaka Y, Miyagi M, Sakai K, Ishikawa Y, Shibuya K, Hase H, Aikawa A. Expression of ACE and ACE2 in individuals with diabetic kidney disease and healthy controls. Am J Kidney Dis 51: 613-623, 2008.
37. Mulder GM, Melenhorst WB, Celie JW, Kloosterhuis NJ, Hillebrands JL, Ploeg RJ, Seelen MA, Visser L, van Dijk MC, van GH. ADAM17 up-regulation in renal transplant dysfunction and non-transplant-related renal fibrosis. Nephrol Dial Transplant 27: 2114-2122, 2012.
38. Nadarajah R, Milagres R, Dilauro M, Gutsol A, Xiao F, Zimpelmann J, Kennedy C, Wysocki J, Batlle D, Burns KD. Podocyte-specific overexpression of human angiotensin-converting enzyme 2 attenuates diabetic nephropathy in mice. Kidney Int 82: 292-303, 2012.
39. Oudit GY, Liu GC, Zhong J, Basu R, Chow FL, Zhou J, Loibner H, Janzek E, Schuster M, Penninger JM, Herzenberg AM, Kassiri Z, Scholey JW. Human recombinant ACE2 reduces the progression of diabetic nephropathy. Diabetes 59: 529-538, 2010.
40. Park SE, Kim WJ, Park SW, Park JW, Lee N, Park C, Youn BS. High urinary ACE2 concentrations are associated with severity of glucose intolerance and microalbuminuria. Eur J Endocrinol 168: 203-210, 2013.
41. Reich HN, Oudit GY, Penninger JM, Scholey JW, Herzenberg AM. Decreased glomerular and tubular expression of ACE2 in patients with type 2 diabetes and kidney disease. Kidney Int 74: 1610-1616, 2008.
42. Ryan MJ, Johnson G, Kirk J, Fuerstenberg SM, Zager RA, Torok- Storb B. HK-2: an immortalized proximal tubule epithelial cell line from normal adult human kidney. Kidney Int 45: 48-57, 1994.
43. Scheller J, Chalaris A, Garbers C, Rose-John S. ADAM17: a molecular switch to control inflammation and tissue regeneration. Trends Immunol 32: 380-387, 2011.
44. Shaltout HA, Westwood BM, Averill DB, Ferrario CM, Figueroa JP, Diz DI, Rose JC, Chappell MC. Angiotensin metabolism in renal proximal tubules, urine, and serum of sheep: evidence for ACE2-dependent processing of angiotensin II. Am J Physiol Renal Physiol 292: F82-F91, 2007.
45. Soler MJ, Wysocki J, Ye M, Lloveras J, Kanwar Y, Batlle D. ACE2 inhibition worsens glomerular injury in association with increased ACE expression in streptozotocin-induced diabetic mice. Kidney Int 72: 614-623, 2007.
46. Soro-Paavonen A, Gordin D, Forsblom C, Rosengard-Barlund M, Waden J, Thorn L, Sandholm N, Thomas MC, Groop PH. Circulating ACE2 activity is increased in patients with type 1 diabetes and vascular complications. J Hypertens 30: 375-383, 2012.
47. Su Z, Zimpelmann J, Burns KD. Angiotensin-(1-7) inhibits angiotensin II-stimulated phosphorylation of MAP kinases in proximal tubular cells. Kidney Int 69: 2212-2218, 2006.
48. Thomas MC, MacIsaac RJ, Jerums G, Weekes A, Moran J, Shaw JE, Atkins RC. Nonalbuminuric renal impairment in type 2 diabetic patients and in the general population (national evaluation of the frequency of renal impairment cO-existing with NIDDM [NEFRON] 11). Diabetes Care 32: 1497-1502, 2009.
49. Tikellis C, Johnston CI, Forbes JM, Burns WC, Burrell LM, Risvanis J, Cooper ME. Characterization of renal angiotensin-converting enzyme 2 in diabetic nephropathy. Hypertension 41: 392-397, 2003.
50. Tipnis SR, Hooper NM, Hyde R, Karran E, Christie G, Turner AJ. A human homolog of angiotensin-converting enzyme. Cloning and functional expression as a captopril-insensitive carboxypeptidase. J Biol Chem 275: 33238-33243, 2000.
51. Wang G, Lai FM, Lai KB, Chow KM, Kwan CH, Li KT, Szeto CC. Urinary mRNA expression of ACE and ACE2 in human type 2 diabetic nephropathy. Diabetologia 51: 1062-1067, 2008.
52. Warner FJ, Lew RA, Smith AI, Lambert DW, Hooper NM, Turner AJ. Angiotensin-converting enzyme 2 (ACE2), but not ACE, is preferentially localized to the apical surface of polarized kidney cells. J Biol Chem 280: 39353-39362, 2005.
53. Watanabe T, Barker TA, Berk BC. Angiotensin II and the endothelium: diverse signals and effects. Hypertension 45: 163-169, 2005.
54. Wei S, Xie Z, Filenova E, Brew K. Drosophila TIMP is a potent inhibitor of MMPs and TACE: similarities in structure and function to TIMP-3. Biochemistry 42: 12200-12207, 2003.
55. Whaley-Connell AT, Chowdhury NA, Hayden MR, Stump CS, Habibi J, Wiedmeyer CE, Gallagher PE, Tallant EA, Cooper SA, Link CD, Ferrario C, Sowers JR. Oxidative stress and glomerular filtration barrier injury: role of the renin-angiotensin system in the Ren2 transgenic rat. Am J Physiol Renal Physiol 291: F1308-F1314, 2006.
56. Wong DW, Oudit GY, Reich H, Kassiri Z, Zhou J, Liu QC, Backx PH, Penninger JM, Herzenberg AM, Scholey JW. Loss of angiotensinconverting enzyme-2 (Ace2) accelerates diabetic kidney injury. Am J Pathol 171: 438-451, 2007.
57. Woroniecka KI, Park AS, Mohtat D, Thomas DB, Pullman JM, Susztak K. Transcriptome analysis of human diabetic kidney disease. Diabetes 60: 2354-2369, 2011.
58. Wysocki J, Garcia-Halpin L, Ye M, Maier C, Sowers K, Burns KD, Batlle D. Regulation of urinary ACE2 in diabetic mice. Am J Physiol Renal Physiol 305: F600-F611, 2013.
59. Wysocki J, Ye M, Soler MJ, Gurley SB, Xiao HD, Bernstein KE, Coffman TM, Chen S, Batlle D. ACE and ACE2 activity in diabetic mice. Diabetes 55: 2132-2139, 2006.
60. Xiao F, Hiremath S, Knoll G, Zimpelmann J, Srivaratharajah K, Jadhav D, Fergusson D, Kennedy CR, Burns KD. Increased urinary Angiotensin-converting enzyme 2 in renal transplant patients with diabetes. PLoS One 7: e37649, 2012.
61. Yamaleyeva LM, Gilliam-Davis S, Almeida I, Brosnihan KB, Lindsey SH, Chappell MC. Differential regulation of circulating and renal ACE2 and ACE in hypertensive mRen2.Lewis rats with early-onset diabetes. Am J Physiol Renal Physiol 302: F1374-F1384, 2012.
62. Ye M, Wysocki J, Naaz P, Salabat MR, LaPointe MS, Batlle D. Increased ACE 2 and decreased ACE protein in renal tubules from diabetic mice: a renoprotective combination? Hypertension 43: 1120-1125, 2004